EAST WINDSOR, N.J.-- (BUSINESS WIRE) -- NexMed, Inc. (Nasdaq: NEXM), a developer of innovative topical products based on the NexACT^® technology, today announced that management will hold a conference call to discuss 2009 third quarter financial results and ongoing corporate activities, on Tuesday, November 10, 2009 at 10:00 a.m. EST. The Company will file its Form 10-Q by the end of business on Monday, November 9, 2009.

In addition, NexMed also announced that it is currently in late stage contract negotiations to lease its facility. Mark Westgate, NexMed’s Chief Financial Officer stated, “If we successfully close this transaction, our monthly cash burn will drop significantly. The tenant will assume all building expenses and the rental income will exceed our mortgage obligations, thereby resulting in a positive cash flow for us.”

The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay pass codes 286 and 337111 are both required for playback. The conference call will also be Webcast live at URL http://www.investorcalendar.com/IC/CEPage.asp?ID=151979. The Webcast replay will be available for three months.

About NexMed

NexMed’s pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a P 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to our ability to successfully close on the leasing of our facility, entering into development and commercialization agreements and obtaining regulatory approval for our products under development, entering into a strategic transaction for the company, pursuing growth opportunities, and/or other factors, some of which are outside our control.